The data de-risk two Phase 3 strategies in a large, RAS G12D PDAC market (~40% of pancreatic cancer cases) with no approved targeted therapy. Monitor enrollment and interim updates for RASolute 305 and initiation of RASolute 309. The 82% ORR in first-line with mFFX is best-in-class potential, but final Phase 3 OS data are needed for approval. Hold / accumulate on further de-risking.
Drugs in focus
RVMD drug pipeline →daraxonrasib
▲ Bullish Named in this press release- Impact
- Phase
- Phase 3 (completed with positive results) / pre-NDA
- Time to market
- NDA submission pending; potential approval in 2L PDAC possibly by Q3 2026 per Truist analyst projection, though no PDUFA date is confirmed
- Next catalyst
- None dated
What to watchDaraxonrasib's Phase 3 success in 2L pancreatic cancer is already priced in after the stock surged near its 52-week high. Near-term upside hinges on formal NDA acceptance and a confirmed PDUFA date. Watch for the NDA filing announcement, which could trigger a smaller bump, but the big binary is behind us. The real long-term story is the broader pipeline (RASolute 303 in 1L PDAC, RASolve 301 in NSCLC), those future readouts are multi-year catalysts.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 2 $189.24entry
- T+1 · 4mo ago +0.40%α −0.48% · $189.99
- T+5 · 4mo ago +1.00%α +0.07% · $191.13
- T+20 · 4mo ago +1.55%α +1.96% · $192.17
- T+60 · 7w ago +5.61%α +2.60% · $199.86
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Revolution Medicines reported positive Phase 1/2 data for zoldonrasib in RAS G12D metastatic pancreatic cancer at ESMO GI 2026. In previously untreated patients, zoldonrasib plus chemotherapy showed an 82% objective response rate (ORR) with mFFX and a 61% ORR with GnP. In previously treated patients, the zoldonrasib plus daraxonrasib doublet achieved a 50% ORR and 9.6-month median progression-free survival in second-line, supporting two Phase 3 trials (RASolute 305 ongoing, RASolute 309 planned).
Key Facts
- Zoldonrasib plus mFFX in first-line metastatic RAS G12D PDAC: 82% ORR, 96% DCR (n=41).
- Zoldonrasib plus GnP in first-line: 61% ORR, 90% DCR (n=40).
- Zoldonrasib plus daraxonrasib in second-line: 50% ORR, 97% DCR, median PFS 9.6 months (n=30).
- Third-line-plus doublet: 47% ORR, 90% DCR, median OS 10.5 months (n=30).
- Safety manageable with no Grade 5 TRAEs; discontinuation due to TRAEs low (2-5%).
- Data support planned Phase 3 RASolute 309 trial of zoldonrasib plus daraxonrasib vs GnP in first-line.
- RAS G12D is the most prevalent RAS mutation subtype in PDAC (40% of patients), with ~61,000 new US cases/year across all cancers.
Financial Impact
Positive Phase 1/2 data for zoldonrasib-based regimens in RAS G12D pancreatic cancer; supports pivotal Phase 3 trials and expands target market beyond the prior daraxonrasib monotherapy. No revenue or financial guidance provided.
Risk Factors
- Phase 3 trials (RASolute 305, 309) may fail to replicate Phase 1/2 efficacy or show OS benefit.
- Safety profile with combination regimens may limit the tolerability in broader patient population.
- Competing RAS-targeted therapies (e.g., from Amgen, Mirati/BMS) could enter the same indication.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3321282 |
Track record
44 reports on RVMD
6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers